Analysis of the efficacy of transcutaneous electrical acupoint stimulation in the treatment of drug-refractory epilepsy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076178

Enrollment

Unknown

Registered

2023-09-26

Start date

2023-10-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-refractory epilepsy

Interventions

Treatment group:Transcutaneous electrical acupoint stimulation

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of drug-resistant epilepsy; 2. Aged 18-60 years old; 3. Comprehensive preoperative evaluation of epilepsy, including medical history, imaging, SEEG intracranial electrode implantation; 4. Understand clinical trial protocol and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The neuroimaging examination clearly is caused by cerebrovascular disease, tumor and other factors of epilepsy patients; 2. Patients with serious cardiovascular, cerebrovascular, liver, kidney, hematopoietic system and other primary diseases or systemic failure; 3. Patients with IQ < 70 and mental, cognitive, and psychological disorders cannot sign informed consent or cooperate with treatment.

Design outcomes

Primary

Measure	Time frame
EEG monitoring;	—

Secondary

Measure	Time frame
Quality of Life in Epilepsy Questionnaire (QOLIE-31);	—

Countries

China

Contacts

Public ContactChunqing Zhang

the Second Affiliated Hospital, Army Medical University

cqzhang@tmmu.edu.cn+86 189 8320 4130

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026